We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Masimo (MASI) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Masimo (MASI - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Masimo is a member of our Medical group, which includes 1067 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Masimo is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for MASI's full-year earnings has moved 10.2% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, MASI has gained about 11.8% so far this year. At the same time, Medical stocks have gained an average of 7.4%. This shows that Masimo is outperforming its peers so far this year.
Another stock in the Medical sector, CochLear Ltd. Unsponsored ADR (CHEOY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 10.2%.
For CochLear Ltd. Unsponsored ADR, the consensus EPS estimate for the current year has increased 8.8% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Masimo belongs to the Medical - Instruments industry, a group that includes 91 individual stocks and currently sits at #88 in the Zacks Industry Rank. Stocks in this group have gained about 6.2% so far this year, so MASI is performing better this group in terms of year-to-date returns.
In contrast, CochLear Ltd. Unsponsored ADR falls under the Medical Services industry. Currently, this industry has 59 stocks and is ranked #96. Since the beginning of the year, the industry has moved +5.7%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Masimo and CochLear Ltd. Unsponsored ADR as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Masimo (MASI) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Masimo (MASI - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Masimo is a member of our Medical group, which includes 1067 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Masimo is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for MASI's full-year earnings has moved 10.2% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, MASI has gained about 11.8% so far this year. At the same time, Medical stocks have gained an average of 7.4%. This shows that Masimo is outperforming its peers so far this year.
Another stock in the Medical sector, CochLear Ltd. Unsponsored ADR (CHEOY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 10.2%.
For CochLear Ltd. Unsponsored ADR, the consensus EPS estimate for the current year has increased 8.8% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Masimo belongs to the Medical - Instruments industry, a group that includes 91 individual stocks and currently sits at #88 in the Zacks Industry Rank. Stocks in this group have gained about 6.2% so far this year, so MASI is performing better this group in terms of year-to-date returns.
In contrast, CochLear Ltd. Unsponsored ADR falls under the Medical Services industry. Currently, this industry has 59 stocks and is ranked #96. Since the beginning of the year, the industry has moved +5.7%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Masimo and CochLear Ltd. Unsponsored ADR as they could maintain their solid performance.